LILLY I3Y-MC-JPBL-Breast-A Randomised, double-blind, placebo-controlled, -Phase 3 study of fluvestrant with or without LY2835219, a CDK4/6 inhibitor, for women with hormone receptor positive, HER2 negative metastatic breast cancer and disease progression after prior endocrine therapy.

A Randomised, double-blind, placebo-controlled, -Phase 3 study of fluvestrant with or without LY2835219, a CDK4/6 inhibitor, for women with hormone receptor positive, HER2 negative metastatic breast cancer and disease progression after prior endocrine therapy.

LILLY I3Y-MC-JPBL-Breast
Cancer
Peter Bushunow, MD
Enrolling
Rachel O'Loughlin, RN
(585) 747-4555
(585) 922 - 5665